Immunotherapeutic Strategies - Key Publications



Publications are listed according to year, with the most recent first. Within each year, publications are listed in alphabetical order, based on the first author’s surname. Click on “Publication link” to access the publication on PubMed. Use the search box above to find particular publications based on author or terms in the title.


  • Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

    Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C.

    Blood. 2010 Sep 16;116(11):1908-18. doi: 10.1182/blood-2009-11-249474. Epub 2010 Jun 8.

  • Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets

    Hislop AD, Palendira U, Leese AM, Arkwright PD, Rohrlich PS, Tangye SG, Gaspar HB, Lankester AC, Moretta A, Rickinson AB.

    Blood. 2010 Oct 28;116(17):3249-57.

  • Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations

    Jaberipour M, Vass SO, Guise CP, Grove JI, Knox RJ, Hu L, Hyde EI, Searle PF.

    Biochem Pharmacol. 2010 Jan 15;79(2):102-11.

  • The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs

    Jefferis R.

    Biotechnol Genet Eng Rev. 2010;26:1-42.

  • Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display

    Leung CS, Haigh TA, Mackay LK, Rickinson AB, Taylor GS.

    Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2165-70.

  • Immunotherapy for Epstein-Barr virus-associated malignancies

    Long, H.M., G. Parsonage, C.P. Fox and S.P. Lee.

    Drug News Perspect. 2010 23. 221-228